The Type and Impact of Evidence Review Group Exploratory Analyses in the NICE Single Technology Appraisal Process

被引:4
|
作者
Carroll, Christopher [1 ]
Kaltenthaler, Eva [1 ]
Hill-McManus, Daniel [2 ]
Scope, Alison [1 ]
Holmes, Michael [1 ]
Rice, Stephen [3 ]
Rose, Micah [4 ]
Tappenden, Paul [1 ]
Woolacott, Nerys [5 ]
机构
[1] Univ Sheffield, Sheffield, S Yorkshire, England
[2] Bangor Univ, Bangor, Gwynedd, Wales
[3] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England
[4] Univ Southampton, Southampton, Hants, England
[5] Univ York, York, N Yorkshire, England
关键词
evidence review groups (ERGS); health policy; National Institute for Health and Care Excellence (NICE); single technology appraisal (STA); HEALTH; SUBMISSIONS;
D O I
10.1016/j.jval.2016.08.729
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: As part of the UK National Institute for Health and Care Excellence (NICE) single technology appraisal process, independent evidence review groups (ERGS) critically appraise a company's submission relating to a specific technology and indication. Objectives: To explore the type of additional exploratory analyses conducted by ERGS and their impact on the recommendations made by NICE. Methods: The 100 most recently completed single technology appraisals with published guidance were selected for inclusion. A content analysis of relevant documents was undertaken to identify and extract relevant data, and narrative synthesis was used to rationalize and present these data. Results: The types of exploratory analysis conducted in relation to companies' models were fixing errors, addressing violations, addressing matters of judgment, and the provision of a new, ERG-preferred base case. Ninety-three of the 100 ERG reports contained at least one of these analyses. The most frequently reported type of analysis in these 93 ERG reports related to the category "Matters of judgment," which was reported in 83 reports (89%). At least one of the exploratory analyses conducted and reported by an ERG is mentioned in 97% of NICE appraisal consultation documents and 94% of NICE final appraisal determinations, and had a clear influence on recommendations in 72% of appraisal consultation documents and 47% of final appraisal determinations. Conclusions: These results suggest that the additional analyses undertaken by ERGS in the appraisal of company submissions are highly influential in the policy-making and decision making process.
引用
收藏
页码:785 / 791
页数:7
相关论文
共 50 条
  • [41] Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Sabine E. Grimm
    Debra Fayter
    Bram L. T. Ramaekers
    Svenja Petersohn
    Rob Riemsma
    Nigel Armstrong
    Xavier Pouwels
    Willem Witlox
    Caro Noake
    Gillian Worthy
    Jos Kleijnen
    Manuela A. Joore
    PharmacoEconomics, 2019, 37 : 1195 - 1207
  • [42] Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
    Wade, Ros
    Grosso, Alessandro
    South, Emily
    Rothery, Claire
    Saramago, Pedro
    Schmitt, Laetitia
    Wright, Kath
    Palmer, Stephen
    PHARMACOECONOMICS, 2019, 37 (02) : 131 - 139
  • [43] Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Peter Auguste
    Jill Colquitt
    Martin Connock
    Emma Loveman
    Rachel Court
    Olga Ciccarelli
    Carl Counsell
    Xavier Armoiry
    PharmacoEconomics, 2020, 38 : 527 - 536
  • [44] Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
    Ros Wade
    Alessandro Grosso
    Emily South
    Claire Rothery
    Pedro Saramago
    Laetitia Schmitt
    Kath Wright
    Stephen Palmer
    PharmacoEconomics, 2019, 37 : 131 - 139
  • [45] Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Rafia, Rachid
    Pandor, Abdullah
    Davis, Sarah
    Stevens, John W.
    Harnan, Sue
    Clowes, Mark
    Sorour, Youssef
    Cutting, Robert
    PHARMACOECONOMICS, 2018, 36 (10) : 1143 - 1151
  • [46] Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Tappenden, Paul
    Carroll, Christopher
    Stevens, John W.
    Rawdin, Andrew
    Grimm, Sabine
    Clowes, Mark
    Kaltenthaler, Eva
    Ingram, John R.
    Collier, Fiona
    Ghazavi, Mohammad
    PHARMACOECONOMICS, 2017, 35 (08) : 805 - 815
  • [47] Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Auguste, Peter
    Colquitt, Jill
    Connock, Martin
    Loveman, Emma
    Court, Rachel
    Ciccarelli, Olga
    Counsell, Carl
    Armoiry, Xavier
    PHARMACOECONOMICS, 2020, 38 (06) : 527 - 536
  • [48] Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Gallacher, Daniel
    Armoiry, Xavier
    Auguste, Peter
    Court, Rachel
    Mantopoulos, Theodoros
    Patterson, Jacoby
    Santis, Maria De
    Cresswell, Joanne
    Mistry, Hema
    PHARMACOECONOMICS, 2019, 37 (01) : 19 - 27
  • [49] Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Rachid Rafia
    Abdullah Pandor
    Sarah Davis
    John W. Stevens
    Sue Harnan
    Mark Clowes
    Youssef Sorour
    Robert Cutting
    PharmacoEconomics, 2018, 36 : 1143 - 1151
  • [50] Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Bram L. T. Ramaekers
    Robert F. Wolff
    Xavier Pouwels
    Marije Oosterhoff
    Anoukh Van Giessen
    Gill Worthy
    Caro Noake
    Nigel Armstrong
    Jos Kleijnen
    Manuela A. Joore
    PharmacoEconomics, 2018, 36 : 917 - 927